Search | Clinical Trials Finder

Conditions: Estrogen Receptor Negative Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Triple Negative Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Triple-negative Breast Cancer
Interventions: cisplatin, laboratory biomarker analysis, pharmacological study, dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI, GDC -0941; Drug · Other · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 16
States / cities: Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 13 more

Conditions: Hemophilia A
Interventions: BAY94-9027; Biological
Lead sponsor: Bayer; Industry
Eligibility: 12 Years to 65 Years · Male only
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 14
States / cities: Tucson, Arizona • Sacramento, California • San Diego, California + 11 more

Conditions: Hemostasis, General Surgery
Interventions: sFilm-FS, TACHOSIL®; Combination Product
Lead sponsor: Sealantium Medical Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: AML, Acute Myeloid Leukemia, Myelodysplastic Disorders
Interventions: Idarubicin, Sorafenib, Ara-C; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years to 60 Years
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Head and Neck Cancer, Carcinoma, Squamous
Interventions: Oxaliplatin, Docetaxel, Cetuximab; Drug
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Myocardial Infarction
Interventions: Not listed
Lead sponsor: University of Vermont; Other
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: EGFR Gene Mutation, Nonsmall Cell Lung Cancer
Interventions: Dasatinib, Osimertinib; Drug
Lead sponsor: Chul Kim; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Hackensack, New Jersey

Conditions: Myelodysplastic Syndromes
Interventions: filgrastim, clofarabine, cytarabine, microarray analysis, biopsy; Biological · Drug · Genetic + 1 more
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 120 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Myelodysplastic Syndrome
Interventions: Erlotinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Hidradenitis Suppurativa (HS)
Interventions: IFX-1, Placebo; Drug
Lead sponsor: InflaRx GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 179 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 13
States / cities: Birmingham, Alabama • Fort Myers, Florida • Miami, Florida + 9 more

Conditions: Metastatic Breast Cancer
Interventions: Pertuzumab, Trastuzumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 16
States / cities: Tucson, Arizona • Duarte, California • Stanford, California + 13 more

Conditions: Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Metastatic
Interventions: FOLFIRNINOX, Losartan, 9-ING-41; Drug
Lead sponsor: Colin D. Weekes, M.D., PhD; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 4
States / cities: Aurora, Colorado • Boston, Massachusetts • Charlestown, Massachusetts + 1 more

Conditions: Prostate Cancer
Interventions: Docetaxel, Docetaxel and GM-CSF; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Male only
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 4
States / cities: San Francisco, California • Boston, Massachusetts • Portland, Oregon + 1 more

Conditions: Burns, Skin Graft Complications
Interventions: Tranexamic acid, Thrombin JMI, skin graft; Drug · Procedure
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Ischemic Stroke
Interventions: Low Dose Argatroban, High Dose Argatroban, rt-PA (alteplase); Drug
Lead sponsor: Andrew D. Barreto, MD; Other
Eligibility: 18 Years and older
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Interventions: TAS6417, CYP Cocktail, Transporter Cocktail; Drug
Lead sponsor: Taiho Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 18
States / cities: Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 15 more

Conditions: Lung Cancer
Interventions: Osimertinib, Cisplatin or Carboplatin; Pemetrexed or Paclitaxel, Radiation; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: La Jolla, California • Palo Alto, California

Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: choline magnesium trisalicylate, idarubicin, cytarabine, laboratory biomarker analysis; Drug · Other
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Multiple Myeloma, Primary Amyloidosis
Interventions: Melphalan, Stem Cell Infusion, Questionnaires, Granulocyte-colony stimulating factor (G-CSF), Apheresis; Drug · Procedure · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 60 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Coronary Disease
Interventions: rNAPc2; Drug
Lead sponsor: ARCA Biopharma, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Lymphoma
Interventions: Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Dexamethasone, Autologous Tumor Cell-Based Vaccine, IL-2; Drug · Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2021
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Advanced Lung Cancer
Interventions: BNT324, BNT327; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 17
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 13 more

Conditions: Graft-vs-Host Disease
Interventions: Recombinant Human Keratinocyte Growth Factor (rHuKGF); Drug
Lead sponsor: FDA Office of Orphan Products Development; Federal
Eligibility: 3 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: HIV Infections
Interventions: Filgrastim, Epoetin alfa, Zidovudine; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer

A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A

A Study Evaluating the Safety and Preliminary Efficacy of sFilm-FS in Controlling Parenchymal Bleeding During Elective Hepatic Surgery

Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)

Oxaliplatin and Docetaxel Followed by Cetuximab for Head and Neck Cancer

Novel Biomarkers of Thrombotic Risk

Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations

Clofarabine, Cytarabine, and G-CSF in Treating Patients With Myelodysplastic Syndromes

Erlotinib Study for Myelodysplastic Syndrome (MDS)

Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)

A Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast Cancer (MBC) With Central Nervous System (CNS) Progression Post-Radiotherapy

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)

Burn Study- Tranexamic Acid Versus Thrombin in Split Thickness Skin Graft

Randomized Controlled Trial of Argatroban With Tissue Plasminogen Activator (tPA) for Acute Stroke

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations

Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia

Trial of Two Stem Cell Doses To Reduce Transplant Induced Symptom Burden

Anticoagulation With rNAPc2 to Eliminate MACE/TIMI 32

Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer

Keratinocyte Growth Factor to Prevent Acute GVHD

An Open-Label Phase I/II Study of Recombinant Granulocyte Colony Stimulating Factor (r-metHuG-CSF) and Recombinant Erythropoietin (rHuEPO) Given Subcutaneously Along With Zidovudine (AZT) to Patients With the Acquired Immune Deficiency Syndrome (AIDS) or Severe AIDS-Related Complex (ARC)